Lindbrook Capital’s AC Immune ACIU Stock Holding History

Lindbrook Capital’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-500	Closed	-$4K	–	1668
2019 Q4	$4K	Buy	+500	New	+$3.33K	﹤0.01%	1127

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Lindbrook Capital's ACIU Position: Q1 2020 in Review

Lindbrook Capital sold out of AC Immune (ACIU) in Q1 2020, closing a stake of 500 shares — an estimated $4K sold.

Lindbrook Capital first reported a position in ACIU in Q4 2019 and held it in 1 quarter. The position peaked at $4K in Q4 2019. 50 funds tracked by Wall St. Rank hold ACIU as of Q1 2020.

Lindbrook Capital reported no remaining AC Immune position as of Q1 2020 after selling out during the quarter.
Lindbrook Capital sold 500 AC Immune shares in Q1 2020, an estimated $4K.
Lindbrook Capital first reported a position in AC Immune in Q4 2019 and held it in 1 quarter.
Lindbrook Capital's AC Immune position peaked at $4K in Q4 2019.
50 funds tracked by Wall St. Rank held AC Immune as of Q1 2020.

Based on Lindbrook Capital's 13F filing for Q1 2020, filed 22 Apr 2020.